GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor

M. Rubenstein, M. Shaw, P. Targonski, C. F. McKiel, A. Dubin, P. Guinan

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


GM-CSF (granulocyte-macrophage-derived colony-stimulating factor) is a differentiation agent that stimulates bone marrow activity in patients receiving chemotherapy. GM-CSF (1 μg/ml daily for 10 days), administered intralesionally, was evaluated to determine whether it would restore a more differentiated phenotype to an anaplastic, rapidly growing, hormone-independent variant (R3327 MAT-LyLu) of the Dunning prostatic adenocarcinoma. Immunohistology was used to quantitate the expression of epithelial growth factor receptors (rEGF) and the tissue testosterone content. GM-CSF therapy significantly (P<0.05) restored rEGF expression and tissue testosterone to levels associated with better differentiated, slower growing, androgen-dependent Dunning variants (R3327 H and G). GM-CSF may have a role in treatment of prostatic cancers by promoting androgen and epithelial growth factor regulation.

Original languageEnglish (US)
Pages (from-to)309-312
Number of pages4
JournalUrological Research
Issue number5
StatePublished - Sep 1991


  • Differentiation
  • Dunning tumor
  • GM-CSF
  • Growth factors
  • Prostate
  • Therapy

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor'. Together they form a unique fingerprint.

Cite this